(Q34326503)

1 August 2017

1 reference

title

Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience (English)

1 reference

1 August 2017

main subject

phase II clinical trial

0 references

1 reference

Sirohi B

1

1 reference

1 August 2017

Kulkarni S

series ordinal

2

1 reference

1 August 2017

Powles R

series ordinal

3

1 reference

1 August 2017

publication date

1 July 2001

1 reference

1 August 2017

published in

Seminars in Hematology

1 reference

1 August 2017

volume

38

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

209-218

1 reference

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

High-dose melphalan for multiple myeloma: long-term follow-up data

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

High-dose busulfan in patients with myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Multiple myeloma treated with high dose intravenous melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990012-5

7 January 2021

10.1016/S0037-1963(01)90012-5

Identifiers

DOI

1 reference

1 August 2017

1 reference